Ann: Botanix Webinar - 15 April 2025 - Registration Information, page-32

From Euroz recent report

BOT trades at 41% discount to comparable asx listed companies, …
do they mention what companies?

Bot should rerate overnight 41% no reason for this discount especially with no more capital raises



“
Our valuation is predicated on Sofdra capturing ~2.5% of U.S. hyperhidrosis patients over the next decade, with a conservative 50% refill rate (~6 Scripts per patient) and 75% reimbursement. If refill rates persist at the current ~100%, our valuation increases to $1.64. As a cross-check, BOT trades at a ~41% discount to average sales multiples of comparable ASX biotechs at launch; applying these to our forecasts implies ~$0.72|”